PDS Biotechnology Corp
PDSB evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $55.5M
- Lead Asset:
- infectimune
What it means
What to watch
Prepared research question
What matters most for PDSB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PDSB
PDS Biotechnology Corp (PDSB) is a clinical-stage immunotherapy company that has discontinued its Phase 3 trial of PDS0101 and refocused on PDS0301 for metastatic colorectal cancer, while facing a going-concern risk due to limited cash resources.
Key risk: Going-concern risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$55.5M
Cash Runway
—
Lead Asset
infectimune
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 2 clinical trials for PDS Biotechnology Corp.
Similar companies
PDS Biotechnology Corp (PDSB) is a clinical-stage immunotherapy company that has discontinued its Phase 3 trial of PDS0101 and refocused on PDS0301 for metastatic colorectal cancer, while facing a going-concern risk due to limited cash resources.
- As of June 30, 2026, PDS Biotech had $5.6 million in cash and cash equivalents and reported a net loss of $9.8 million for the quarter [sec].
- The company announced a strategic refocus to prioritize PDS0301 in metastatic colorectal cancer and discontinued the VERSATILE-003 Phase 3 trial of PDS0101 [news · published 2026-08-11].
- As of December 31, 2025, the accumulated deficit was $216.6 million [sec_mda · as of 2026-08-13].
- PDS Biotech has concluded that substantial doubt exists about its ability to continue as a going concern [sec_mda · as of 2026-08-13].
- The company is dependent on raising additional capital or securing a strategic partnership to advance PDS0301 through its planned Phase 2b trial [sec_mda · as of 2026-08-13].
What works
- PDS0301 has generated positive Phase 2 clinical and immunological biomarker data in metastatic colorectal cancer, supporting the strategic refocus [news · published 2026-08-13].
- The company is actively pursuing strategic partnerships or externally funded opportunities for PDS0101, which may provide non-dilutive funding [sec_mda · as of 2026-08-13].
What to weigh
- As of June 30, 2026, cash and equivalents were only $5.6 million, and the company has concluded substantial doubt exists about its ability to continue as a going concern [sec_mda · as of 2026-08-13].
- The accumulated deficit grew from $182.1 million at December 31, 2024 to $216.6 million at December 31, 2025 [sec_mda · as of 2026-08-13].
- The strategic refocus on PDS0301 involves significant risks, including that future clinical trials may not replicate Phase 2 results and that the company may not advance PDS0301 on the anticipated timeline or budget [sec_mda · as of 2026-08-13].
- The discontinuation of the VERSATILE-003 trial and limited cash resources may increase investor uncertainty and make it more difficult to obtain financing [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash position and going-concern risk
“As of June 30, 2026, we had $5.6 million in cash and cash equivalents, and we have concluded that substantial doubt exists about our ability to continue as a going concern.”
SEC MD&A · August 13, 2026
Strategic refocus on PDS0301 and discontinuation of VERSATILE-003
“PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101”
News · August 11, 2026
Accumulated deficit
“As of December 31, 2025 and 2024, we had an accumulated deficit of $216.6 and $182.1 million, respectively.”
SEC MD&A · August 13, 2026
Dependence on additional financing
“Our ability to advance PDS0301 through its planned Phase 2b clinical trial and to maintain operations is dependent upon our ability to raise additional capital.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2021-03-29 · Phase 2 start for PDS0101 + pembrolizumab in HNSCC — This trial was part of the now-discontinued VERSATILE-003 program.
- 2025-05-30 · Phase 3 start for PDS0101 + pembrolizumab in HNSCC — This Phase 3 trial was discontinued as part of the strategic refocus announced in August 2026.
Risks & what to watch (4)›
Key risks
- Going-concern risk — Company has concluded substantial doubt exists about its ability to continue as a going concern as of June 30, 2026 [sec_mda · as of 2026-08-13].
- Cash runway — Only $5.6 million in cash and equivalents as of June 30, 2026, with a net loss of $9.8M in the quarter [sec].
- Clinical trial risk — PDS0301 Phase 2 results may not replicate in the planned Phase 2b trial; timeline and budget uncertainties [sec_mda · as of 2026-08-13].
- Financing difficulty — Discontinuation of VERSATILE-003 and limited cash may increase investor uncertainty and hinder financing [sec_mda · as of 2026-08-13].
What to watch
- Ability to raise additional capital or secure a strategic partnership for PDS0101 to fund operations [sec_mda · as of 2026-08-13].
- Initiation and progress of the planned Phase 2b trial for PDS0301 in metastatic colorectal cancer [sec_mda · as of 2026-08-13].
- Any updates on the partnership strategy for PDS0101 and potential non-dilutive funding [news · published 2026-08-11].
- Cash burn rate and whether the company can extend its runway beyond the current $5.6 million [sec].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run PDS Biotechnology Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PDS Biotechnology Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$10M
Lead: Phase 3
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
40
Total value held
$3.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,631,089 | $987K |
| geode capital management, llc | 660,228 | $399K |
| blackrock, inc. | 554,048 | $335K |
| vanguard fiduciary trust co | 307,311 | $186K |
| blair william & co/il | 300,000 | $182K |
| renaissance technologies llc | 220,800 | $134K |
| inspirion wealth advisors, llc | 181,995 | $110K |
| armistice capital, llc | 173,605 | $105K |
| state street corp | 133,333 | $81K |
| wells fargo & company/mn | 110,500 | $67K |
Showing top 10 of 40 institutional holders of PDS Biotechnology Corp. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 3.2%
- Days to cover
- 1.4
- Shares short
- 1,705,936
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PDSB short interestGovernance
Frequently asked questions
What is the AI investment thesis for PDS Biotechnology Corp?
PDS Biotechnology Corp (PDSB) is a clinical-stage immunotherapy company that has discontinued its Phase 3 trial of PDS0101 and refocused on PDS0301 for metastatic colorectal cancer, while facing a going-concern risk due to limited cash resources.
Who is the CEO of PDS Biotechnology Corp?
Dr. Frank K. Bedu-Addo Ph.D. is the chief executive officer of PDS Biotechnology Corp (PDSB).
Where is PDS Biotechnology Corp headquartered?
PDS Biotechnology Corp (PDSB) is headquartered in Princeton, NJ, United States.
What therapeutic areas does PDS Biotechnology Corp focus on?
PDS Biotechnology Corp develops therapies across Oncology, Immunology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.